The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis

Hyun Woo Lee, Hyung Jun Kim, Chang Hoon Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aims: Olodaterol is a novel inhaled long-acting β 2 -agonist (LABA) that showed efficacy as a bronchodilator for patients with chronic obstructive pulmonary disease (COPD) and asthma. However, it is unclear whether olodaterol reduces mortality; the safety issues of olodaterol have not been fully evaluated. Methods: Randomized controlled trials comparing olodaterol with placebo for patients with COPD or asthma, which evaluated mortality or serious adverse events, were included. Eighteen trials reporting mortality and 26 trials reporting nonfatal serious adverse events were included. Results: Inhaled olodaterol did not reduce the risk of mortality (Peto fixed OR 1.31; 95% CI 0.90–1.89) and had no significant impacts on nonfatal serious adverse events (Peto fixed OR 1.03; 95% CI 0.91–1.15). Conclusions: Inhaled olodaterol has no impact on mortality risk in clinical trials conducted on patients with COPD and asthma. However, the interpretation is limited by a high OR (1.31) and a wide CI that includes the hazardous effect. We could not find any relationship between inhaled olodaterol use and nonfatal serious adverse events.

Original languageEnglish
Pages (from-to)1166-1175
Number of pages10
JournalBritish Journal of Clinical Pharmacology
Volume83
Issue number6
DOIs
StatePublished - 1 Jan 2017

Fingerprint

Meta-Analysis
Mortality
Chronic Obstructive Pulmonary Disease
Asthma
Bronchodilator Agents
olodaterol
Randomized Controlled Trials
Placebos
Clinical Trials
Safety

Keywords

  • adrenergic β -receptor agonists
  • asthma
  • chronic obstructive pulmonary disease
  • mortality
  • olodaterol

Cite this

@article{77c77bd5606b40209918ba328a3134e0,
title = "The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis",
abstract = "Aims: Olodaterol is a novel inhaled long-acting β 2 -agonist (LABA) that showed efficacy as a bronchodilator for patients with chronic obstructive pulmonary disease (COPD) and asthma. However, it is unclear whether olodaterol reduces mortality; the safety issues of olodaterol have not been fully evaluated. Methods: Randomized controlled trials comparing olodaterol with placebo for patients with COPD or asthma, which evaluated mortality or serious adverse events, were included. Eighteen trials reporting mortality and 26 trials reporting nonfatal serious adverse events were included. Results: Inhaled olodaterol did not reduce the risk of mortality (Peto fixed OR 1.31; 95{\%} CI 0.90–1.89) and had no significant impacts on nonfatal serious adverse events (Peto fixed OR 1.03; 95{\%} CI 0.91–1.15). Conclusions: Inhaled olodaterol has no impact on mortality risk in clinical trials conducted on patients with COPD and asthma. However, the interpretation is limited by a high OR (1.31) and a wide CI that includes the hazardous effect. We could not find any relationship between inhaled olodaterol use and nonfatal serious adverse events.",
keywords = "adrenergic β -receptor agonists, asthma, chronic obstructive pulmonary disease, mortality, olodaterol",
author = "Lee, {Hyun Woo} and Kim, {Hyung Jun} and Lee, {Chang Hoon}",
year = "2017",
month = "1",
day = "1",
doi = "10.1111/bcp.13210",
language = "English",
volume = "83",
pages = "1166--1175",
journal = "British journal of clinical pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",

}

The impact of olodaterol on the risk of mortality and serious adverse events : a systematic review and meta-analysis. / Lee, Hyun Woo; Kim, Hyung Jun; Lee, Chang Hoon.

In: British Journal of Clinical Pharmacology, Vol. 83, No. 6, 01.01.2017, p. 1166-1175.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The impact of olodaterol on the risk of mortality and serious adverse events

T2 - a systematic review and meta-analysis

AU - Lee, Hyun Woo

AU - Kim, Hyung Jun

AU - Lee, Chang Hoon

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Aims: Olodaterol is a novel inhaled long-acting β 2 -agonist (LABA) that showed efficacy as a bronchodilator for patients with chronic obstructive pulmonary disease (COPD) and asthma. However, it is unclear whether olodaterol reduces mortality; the safety issues of olodaterol have not been fully evaluated. Methods: Randomized controlled trials comparing olodaterol with placebo for patients with COPD or asthma, which evaluated mortality or serious adverse events, were included. Eighteen trials reporting mortality and 26 trials reporting nonfatal serious adverse events were included. Results: Inhaled olodaterol did not reduce the risk of mortality (Peto fixed OR 1.31; 95% CI 0.90–1.89) and had no significant impacts on nonfatal serious adverse events (Peto fixed OR 1.03; 95% CI 0.91–1.15). Conclusions: Inhaled olodaterol has no impact on mortality risk in clinical trials conducted on patients with COPD and asthma. However, the interpretation is limited by a high OR (1.31) and a wide CI that includes the hazardous effect. We could not find any relationship between inhaled olodaterol use and nonfatal serious adverse events.

AB - Aims: Olodaterol is a novel inhaled long-acting β 2 -agonist (LABA) that showed efficacy as a bronchodilator for patients with chronic obstructive pulmonary disease (COPD) and asthma. However, it is unclear whether olodaterol reduces mortality; the safety issues of olodaterol have not been fully evaluated. Methods: Randomized controlled trials comparing olodaterol with placebo for patients with COPD or asthma, which evaluated mortality or serious adverse events, were included. Eighteen trials reporting mortality and 26 trials reporting nonfatal serious adverse events were included. Results: Inhaled olodaterol did not reduce the risk of mortality (Peto fixed OR 1.31; 95% CI 0.90–1.89) and had no significant impacts on nonfatal serious adverse events (Peto fixed OR 1.03; 95% CI 0.91–1.15). Conclusions: Inhaled olodaterol has no impact on mortality risk in clinical trials conducted on patients with COPD and asthma. However, the interpretation is limited by a high OR (1.31) and a wide CI that includes the hazardous effect. We could not find any relationship between inhaled olodaterol use and nonfatal serious adverse events.

KW - adrenergic β -receptor agonists

KW - asthma

KW - chronic obstructive pulmonary disease

KW - mortality

KW - olodaterol

UR - http://www.scopus.com/inward/record.url?scp=85009783163&partnerID=8YFLogxK

U2 - 10.1111/bcp.13210

DO - 10.1111/bcp.13210

M3 - Article

C2 - 27957746

AN - SCOPUS:85009783163

VL - 83

SP - 1166

EP - 1175

JO - British journal of clinical pharmacology

JF - British journal of clinical pharmacology

SN - 0306-5251

IS - 6

ER -